First line therapy: have we made any improvement?

被引:5
作者
Bookman, Michael A. [1 ]
机构
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA
关键词
D O I
10.1016/S0959-8049(11)70153-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:S93 / S103
页数:11
相关论文
共 36 条
  • [1] Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
    Alberts, DS
    Liu, PY
    Hannigan, EV
    OToole, R
    Williams, SD
    Young, JA
    Franklin, EW
    ClarkePearson, DL
    Malviya, VK
    DuBeshter, B
    Adelson, MD
    Hoskins, WJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) : 1950 - 1955
  • [2] [Anonymous], J CLIN ONCOL
  • [3] [Anonymous], 2010, Cancer Facts Figures 2010
  • [4] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) : 34 - 43
  • [5] Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study
    Bolis, G
    Danese, S
    Tateo, S
    Rabaiotti, E
    D'Agostino, G
    Merisio, C
    Scarfone, G
    Polverino, G
    Parazzini, F
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 : 74 - 78
  • [6] Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study
    Bolis, Giorgio
    Scarfone, Giovanna
    Raspagliesi, Francesco
    Mangili, Giorgia
    Danese, Saverio
    Scollo, Paolo
    Lo Russo, Domenica
    Villa, Antonella
    Aimone, Paola Daniela
    Scambia, Giovanni
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) : 2905 - 2912
  • [7] Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup
    Bookman, Michael A.
    Brady, Mark F.
    McGuire, William P.
    Harper, Peter G.
    Alberts, David S.
    Friedlander, Michael
    Colombo, Nicoletta
    Fowler, Jeffrey M.
    Argenta, Peter A.
    De Geest, Koen
    Mutch, David G.
    Burger, Robert A.
    Swart, Ann Marie
    Trimble, Edward L.
    Accario-Winslow, Chrisann
    Roth, Lawrence M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1419 - 1425
  • [8] Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study
    De Placido, S
    Scambia, G
    Di Vagno, G
    Naglieri, E
    Lombardi, AV
    Biamonte, R
    Marinaccio, M
    Carteni, G
    Manzione, L
    Febbraro, A
    de Matteis, A
    Gasparini, G
    Valerio, MR
    Danese, S
    Perrone, F
    Lauria, R
    De Laurentiis, M
    Greggi, S
    Gallo, C
    Pignata, S
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) : 2635 - 2642
  • [9] Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
    du Bois, A
    Weber, B
    Rochon, J
    Meier, W
    Goupil, A
    Bricht, S
    Barats, JC
    Kuhn, W
    Orfeuvre, H
    Wagner, U
    Richter, B
    Lueck, HJ
    Pfisterer, J
    Costa, S
    Schroeder, W
    Kimmig, R
    Pujade-Lauraine, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) : 1127 - 1135
  • [10] A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer
    du Bois, A
    Lück, HJ
    Meier, W
    Adams, HP
    Möbus, V
    Costa, S
    Bauknecht, T
    Richter, B
    Warm, M
    Schröder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    Emons, G
    Wagner, U
    Kuhn, W
    Pfisterer, J
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17): : 1320 - 1330